(Colorectal Cancer) Panitumumab + mFOLFOXIRI Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On June 6, 2022, Daniele Rossini et al. from the University of Pisa published in the medical journal Journal of Clinical Oncology the efficacy and safety results of panitumumab plus mFOLFOXIRI as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer in the TRIPLETE Phase III clinical trial.
The TRIPLETE Phase III trial randomized patients with RAS/BRAF wild-type metastatic colorectal cancer (N=435) in a 1:1 ratio into the panitumumab + mFOLFOXIRI group (N=218) and the panitumumab + mFOLFOX group (N=217). After 12 cycles, both groups continued with fluorouracil + leucovorin + panitumumab. The primary endpoint was objective response rate (ORR).
The primary endpoint ORR odds ratio was 0.87.
Other results: Early tumor shrinkage rate — panitumumab + mFOLFOXIRI 58% / panitumumab + mFOLFOX 57%; maximum tumor shrinkage rate — panitumumab + mFOLFOXIRI 47% / panitumumab + mFOLFOX 48%; R0 resection rate — panitumumab + mFOLFOXIRI 29% / panitumumab + mFOLFOX 25%; median PFS — panitumumab + mFOLFOXIRI 12.7 months / panitumumab + mFOLFOX 12.3 months.
Based on the TRIPLETE trial results, Daniele Rossini et al. concluded: In patients with RAS/BRAF wild-type metastatic colorectal cancer, panitumumab plus mFOLFOXIRI as first-line treatment showed no significant clinical benefit over panitumumab plus mFOLFOX.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00839
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4